Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein
David Oyen, Jonathan L Torres, Ulrike Wille-Reece, Christian F Ockenhouse, Daniel Emerling, Jacob Glanville, Wayne Volkmuth, Yevel Flores-Garcia, Fidel Zavala, Andrew B Ward, C Richter King, Ian A Wilson, David Oyen, Jonathan L Torres, Ulrike Wille-Reece, Christian F Ockenhouse, Daniel Emerling, Jacob Glanville, Wayne Volkmuth, Yevel Flores-Garcia, Fidel Zavala, Andrew B Ward, C Richter King, Ian A Wilson
Abstract
Acquired resistance against antimalarial drugs has further increased the need for an effective malaria vaccine. The current leading candidate, RTS,S, is a recombinant circumsporozoite protein (CSP)-based vaccine against Plasmodium falciparum that contains 19 NANP repeats followed by a thrombospondin repeat domain. Although RTS,S has undergone extensive clinical testing and has progressed through phase III clinical trials, continued efforts are underway to enhance its efficacy and duration of protection. Here, we determined that two monoclonal antibodies (mAbs 311 and 317), isolated from a recent controlled human malaria infection trial exploring a delayed fractional dose, inhibit parasite development in vivo by at least 97%. Crystal structures of antibody fragments (Fabs) 311 and 317 with an (NPNA)3 peptide illustrate their different binding modes. Notwithstanding, one and three of the three NPNA repeats adopt similar well-defined type I β-turns with Fab311 and Fab317, respectively. Furthermore, to explore antibody binding in the context of P. falciparum CSP, we used negative-stain electron microscopy on a recombinant shortened CSP (rsCSP) construct saturated with Fabs. Both complexes display a compact rsCSP with multiple Fabs bound, with the rsCSP-Fab311 complex forming a highly organized helical structure. Together, these structural insights may aid in the design of a next-generation malaria vaccine.
Trial registration: ClinicalTrials.gov NCT01857869.
Keywords: EM; X-ray crystallography; antibodies; circumsporozoite protein; malaria.
Conflict of interest statement
Conflict of interest statement: W.V. and D.E. are employees of and own equity in Atreca, Inc.
Copyright © 2017 the Author(s). Published by PNAS.
Figures
References
- World Health Organization . World Malaria Report 2016. WHO; Geneva: 2016.
- WHO Malaria Vaccine Funders Group . Malaria Vaccine Technology Roadmap. WHO; Geneva: 2013.
- Agnandji ST, et al. RTS,S Clinical Trials Partnership First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011;365:1863–1875.
- RTS,S Clinical Trials Partnership Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: A phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;11:e1001685.
- RTS,S Clinical Trials Partnership Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31–45.
- Imwong M, Hien TT, Thuy-Nhien NT, Dondorp AM, White NJ. Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam. Lancet Infect Dis. 2017;17:1022–1023.
- Rich KA, George FW, 4th, Law JL, Martin WJ. Cell-adhesive motif in region II of malarial circumsporozoite protein. Science. 1990;249:1574–1577.
- Ancsin JB, Kisilevsky R. A binding site for highly sulfated heparan sulfate is identified in the N terminus of the circumsporozoite protein: Significance for malarial sporozoite attachment to hepatocytes. J Biol Chem. 2004;279:21824–21832.
- Coppi A, et al. Heparan sulfate proteoglycans provide a signal to Plasmodium sporozoites to stop migrating and productively invade host cells. Cell Host Microbe. 2007;2:316–327.
- Nussenzweig V, Nussenzweig RS. Circumsporozoite proteins of malaria parasites. Bull Mem Acad R Med Belg. 1989;144:493–504.
- Plassmeyer ML, et al. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. J Biol Chem. 2009;284:26951–26963.
- Doud MB, et al. Unexpected fold in the circumsporozoite protein target of malaria vaccines. Proc Natl Acad Sci USA. 2012;109:7817–7822.
- Bowman S, et al. The complete nucleotide sequence of chromosome 3 of Plasmodium falciparum. Nature. 1999;400:532–538.
- Lockyer MJ, Schwarz RT. Strain variation in the circumsporozoite protein gene of Plasmodium falciparum. Mol Biochem Parasitol. 1987;22:101–108.
- Bowman NM, et al. Comparative population structure of Plasmodium falciparum circumsporozoite protein NANP repeat lengths in Lilongwe, Malawi. Sci Rep. 2013;3:1990.
- Guy AJ, et al. Insights into the immunological properties of intrinsically disordered malaria proteins using proteome scale predictions. PLoS One. 2015;10:e0141729.
- De Wilde M, Cohen J. 2001. US Patent 6,169,171.
- Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin. 2010;6:90–96.
- Kester KE, et al. RTS,S Vaccine Evaluation Group Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: Safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009;200:337–346.
- Stoute JA, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 1997;336:86–91.
- Regules JA, et al. Fractional third and fourth dose of RTS,S/AS01 malaria candidate vaccine: A phase 2a controlled human malaria parasite infection and immunogenicity study. J Infect Dis. 2016;214:762–771.
- Espinosa DA, et al. Robust antibody and CD8(+) T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection. NPJ Vaccines. 2017;2:10.
- Bruña-Romero O, et al. Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int J Parasitol. 2001;31:1499–1502.
- Zavala F, Cochrane AH, Nardin EH, Nussenzweig RS, Nussenzweig V. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J Exp Med. 1983;157:1947–1957.
- Zavala F, et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science. 1985;228:1436–1440.
- Dyson HJ, Satterthwait AC, Lerner RA, Wright PE. Conformational preferences of synthetic peptides derived from the immunodominant site of the circumsporozoite protein of Plasmodium falciparum by 1H NMR. Biochemistry. 1990;29:7828–7837.
- Ghasparian A, Moehle K, Linden A, Robinson JA. Crystal structure of an NPNA-repeat motif from the circumsporozoite protein of the malaria parasite Plasmodium falciparum. Chem Commun (Camb) 2006:174–176.
- Herrera R, et al. Reversible conformational change in the Plasmodium falciparum circumsporozoite protein masks its adhesion domains. Infect Immun. 2015;83:3771–3780.
- Patra AP, Sharma S, Ainavarapu SR. Force spectroscopy of the Plasmodium falciparum vaccine candidate circumsporozoite protein suggests a mechanically pliable repeat region. J Biol Chem. 2017;292:2110–2119.
- Satterthwait AC, et al. The conformational restriction of synthetic vaccines for malaria. Bull World Health Organ. 1990;68:17–25.
- Bisang C, et al. Stabilization of type-I β-turn conformations in peptides containing the NPNA-repeat motif of the Plasmodium falciparum circumsporozoite protein by substituting proline for (S)-α-methylproline. J Am Chem Soc. 1995;117:7904–7915.
- Stewart MJ, Vanderberg JP. Malaria sporozoites leave behind trails of circumsporozoite protein during gliding motility. J Protozool. 1988;35:389–393.
- Schwenk R, et al. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice. PLoS One. 2014;9:e111020.
- Bruña-Romero O, et al. Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int J Parasitol. 2001;31:1499–1502.
- Anthis NJ, Clore GM. Sequence-specific determination of protein and peptide concentrations by absorbance at 205 nm. Protein Sci. 2013;22:851–858.
- Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307–326.
- McCoy AJ, et al. Phaser crystallographic software. J Appl Crystallogr. 2007;40:658–674.
- Biasini M, et al. SWISS-MODEL: Modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 2014;42:W252–W258.
- Bordoli L, et al. Protein structure homology modeling using SWISS-MODEL workspace. Nat Protoc. 2009;4:1–13.
- Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: A web-based environment for protein structure homology modelling. Bioinformatics. 2006;22:195–201.
- Lepore R, Olimpieri PP, Messih MA, Tramontano A. PIGSPro: Prediction of immunoGlobulin structures v2. Nucleic Acids Res. 2017;45:W17–W23.
- Adams PD, et al. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66:213–221.
- Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66:486–501.
- Connolly ML. The molecular surface package. J Mol Graph. 1993;11:139–141.
- Gelin BR, Karplus M. Side-chain torsional potentials: Effect of dipeptide, protein, and solvent environment. Biochemistry. 1979;18:1256–1268.
- Krissinel E, Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr. 2004;60:2256–2268.
- McDonald IK, Thornton JM. Satisfying hydrogen bonding potential in proteins. J Mol Biol. 1994;238:777–793.
- Lovell SC, et al. Structure validation by Cα geometry: ϕ, ψ and Cβ deviation. Proteins. 2003;50:437–450.
- Suloway C, et al. Automated molecular microscopy: The new Leginon system. J Struct Biol. 2005;151:41–60.
- Lander GC, et al. Appion: An integrated, database-driven pipeline to facilitate EM image processing. J Struct Biol. 2009;166:95–102.
- Voss NR, Yoshioka CK, Radermacher M, Potter CS, Carragher B. DoG Picker and TiltPicker: Software tools to facilitate particle selection in single particle electron microscopy. J Struct Biol. 2009;166:205–213.
- Ogura T, Iwasaki K, Sato C. Topology representing network enables highly accurate classification of protein images taken by cryo electron-microscope without masking. J Struct Biol. 2003;143:185–200.
- Scheres SH. RELION: Implementation of a Bayesian approach to cryo-EM structure determination. J Struct Biol. 2012;180:519–530.
- Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. cryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods. 2017;14:290–296.
- Chen VB, et al. MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66:12–21.
Source: PubMed